All In Biotech

Drug Trial Radar · NCT07897799

The METAMAX Study: MT027 Allogeneic CAR-T for Brain Metastases From Advanced Solid Tumors

A Phase II, Open-label, Multicenter Trial With a Safety Run-in to Evaluate the Safety, Tolerability, Intracranial Efficacy, Pharmacokinetics, and Pharmacodynamics of MT027 Administered Intracerebroventricularly in Patients With B7-H3-positive Brain Metastases From Advanced Solid Tumors

Last checked: Nov 20, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Dec 30, 2027

Primary completion

Dec 20, 2029

Study completion Dec 20, 2030

Sponsor

Lead sponsor
T-MAXIMUM Pharmaceutical IncIndustry
Sponsor type
Industry
First posted
Oct 27, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective, open-label, multicenter, single arm Phase II trial to evaluate the safety, tolerability, intracranial efficacy, pharmacokinetics, and pharmacodynamics of MT027 administered ICV in patients with B7-H3-positive brain metastases from advanced solid tumors. The trial consists of two sequential stages: a safety run-in stage followed by a dose expansion stage. Approximately 40 participants are planned for enrollment, including approximately 3 to 6 participants in the safety run in stage and 34 participants in the dose expansion stage. The final number of participants enrolled may vary depending on the safety findings observed during the safety run-in stage. Approximately 3 to 6 eligible participants from the primary target population will receive MT027 3×107 CAR+ T cells via ICV injection on Days 1 and 15 of each 28-day cycle. DLTs will be assessed during a 28-day DLT observation period following the first dose. Following SRC confirmation of acceptable safety during the safety run-in stage, an additional 34 participants will be enrolled to evaluate the intracranial efficacy of MT027 dosed at 3×107 CAR+ T cells.

Conditions

  • Brain Metastases From Solid Tumors

Interventions

  • Intracerebroventricular injection of MT027 UCAR-T Cell targeting B7H3Biological

    MT027 will be injected intracerebroventricularly at a dose of 3×10\^7 cells on Day 1 \& Day 15 of each 28-day treatment cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence rate of Dose-limiting toxicity (DLT)Time frame: up to 28 days
  2. Intracranial progression-free survival at 6 months (iPFS6)Time frame: up to 6 months

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • Delta Hy Research

    Houston, Texas

  • Chang Gung Memorial Hospital, Linkou

    Taoyuan, Taoyuan, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.